Recent high profile cases have highlighted the importance of establishing the appropriate balance of benefits and risks regarding drug therapy. The regulatory authorities and the pharmaceutical industry are responsible for ensuring drug safety, but prescribers and patients also have responsibilities in this regard. Providing better education for professionals and developing better information for patients are amongst the most important challenges to be faced.
Get full access to this article
View all access options for this article.
References
1.
GoodyearM.Learning from the TGN1412 trial. BMJ 2006; 332:677–8.
2.
House of Commons Health Committee. The influence of the pharmaceutical industry. March2005.www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf accessed 19May2006.
3.
Medicines and Healthcare products Regulatory Agency. www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=20 Accessed 19May2006.
4.
Commission on Human Medicines. Code of Practice on Interests. www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dID=17909&noSaveAs=1&Rendition=WEB Accessed 19May2006.
5.
Association of the British Pharmaceutical Industry Code of Practice for the Pharmaceutical Industry 2006. www.abpi.org.uk/publications/pdfs/pmpca_code2006.pdf Accessed 19May2006.
6.
WallerPCEvansSJW.A model for the future conduct of pharmacovigilance. Pharmacoepidemiology and Drug Safety 2003; 12:17–29.
